| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
| 2021 | A novel anti-tumor/anti-tumor-associated fibroblast/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor | Chen, M; Sheu, MT; Cheng, TL; Roffler, SR ; Lin, SY; Chen, YJ; Cheng, YA; Cheng, JJ; Chang, HY; Wu, TY; Kao, AP; Ho, YS; Chuang, KH | Biomaterials science 10(1), 202-215 | | | |
| 2023 | Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture | Lin, YC; Chen, BM; Tran, TTM; Chang, TC; Al-Qaisi, TS; Roffler, SR | Journal of Controlled Release 354, 354-367 | | | |
| 2023 | Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine) | Bavli, Y; Chen, BM; Gross, G; Hershko, A; Turjeman, K; Roffler, S ; Barenholz, Y | Journal of Controlled Release 354, 316-322 | | | |
| 2020 | Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes | Chen, I-Ju; Cheng, Yi-An; Ho, Kai-Wen; Lin, Wen-Wei; Cheng, Kai-Wen; Lu, Yun-Chi; Hsieh, Yuan-Chin; Huang, Chien-Chiao; Chuang, Chih-Hung; Chen, Fang-Ming; Su, Yu-Cheng; Roffler, Steve R. ; Cheng, Tian-Lu | Acta Biomaterialia 111, 386-397 | | | |
| 2022 | Bispecific T-cell engagers non-covalently decorated drug-loaded PEGylated nanocarriers for cancer immunochemotherapy | Cheng, WJ; Chuang, KH; Lo, YJ; Chen, M; Chen, YJ; Roffler, SR ; Ho, HO; Lin, SY; Sheu, MT | Journal of Controlled Release 344, 235-248 | | | |
| 2019 | Both IgM and IgG Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice. | Chang, TC; Chen, BM; Lin, WW; Yu, PH; Chiu, YW; Chen, YT; Wu, JY; Cheng, TL; Hwang, DY; Roffler, SR | Pharmaceutics 12(1), 15 | | | |
| 2017 | Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. | Su, YC; Burnouf, PA; Chuang, KH; Chen, BM; Cheng, TL; Roffler, SR | NATURE COMMUNICATIONS 8, 15507 | | | |
| 2022 | Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment | Lin, HJ; Liang, TL; Chang, YY; Liu, DZ; Fan, JY; Roffler, SR ; Lin, SY | Pharmaceutics 14(6), 1202 | | | |
| 2008 | Directed evolution of a lysosomal enzyme with enhanced activity at neutral pH by mammalian cell-surface display. | Chen, KC; Wu, CH; Chang, CY; Lu, WC; Tseng, Q; Prijovich, ZM; Schechinger, W; Liaw, YC ; Leu, YL; Roffler, SR | Chemistry & Biology 15(12), 1277-1286 | | | |
| 2021 | Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity | Ho, KW; Chen, IU; Cheng, YA; Liao, TY; Liu, ES; Chen, HJ; Lu, YC; Su, YC; Roffler, SR ; Huang, BC; Liu, HJ; Huang, MY; Chen, CY; Cheng, TL | Journal of nanobiotechnology 19, 16 | | | |
| 2019 | Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs. | Bavli, Y; Winkler, I; Chen, BM; Roffler, S ; Cohen, R; Szebeni, J; Barenholz, Y | Journal of controlled release : official journal of the Controlled Release Society 306, 138-148 | | | |
| 2019 | Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer. | Cheng, YA; Chen, IJ; Su, YC; Cheng, KW; Lu, YC; Lin, WW; Hsieh, YC; Kao, CH; Chen, FM; Roffler, SR ; Cheng, TL | Biomaterials science 7(8), 3404-3417 | | | |
| 2017 | Enhancement Effect of a Variable Topology of a Membrane-Tethered Anti-Poly(ethylene glycol) Antibody on the Sensitivity for Quantifying PEG and PEGylated Molecules. | Lin, WW; Cheng, YA; Kao, CH; Roffler, SR ; Lee, YC; Chen, BM; Hsieh, YC; Chen, IJ; Huang, BC; Wang, YT; Tung, YC; Huang, MY; Chen, FM; Cheng, TL | ANALYTICAL CHEMISTRY 89(11), 6082-6090 | | | |
| 2021 | Entropy-driven binding of gut bacterial β-glucuronidase inhibitors ameliorates irinotecan-induced toxicity | Lin, HY; Chen, CY; Lin, TC; Yeh, LF; Hsieh, WC; Gao, S; Burnouf, PA; Chen, BM; Hsieh, TJ; Dashnyam, P; Kuo, YH; Tu, Z; Roffler, SR ; Lin, CH | Communications biology 4, 280 | | | |
| 2021 | Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma | Fang, JL; Beland, FA; Tang, Y; Roffler, SR | Toxicology reports 8, 148-154 | | | |
| 2022 | Glucuronides: From biological waste to bio-nanomedical applications | Burnouf, PA; Roffler, SR ; Wu, CC; Su, YC | Journal of controlled release : official journal of the Controlled Release Society 349, 765-782 | | | |
| 2021 | Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice | Chang, TC; Chen, BM; Wu, JY; Cheng, TL; Roffler, S | Biomedicine & pharmacotherapy 146, 112502 | | | |
| 2022 | In Vivo Hematopoietic Stem Cell Gene Therapy for SARS-CoV2 Infection Using a Decoy Receptor | Wang, H; Li, C; Obadan, AO; Frizzell, H; Hsiang, TY; Gil, S; Germond, A; Fountain, C; Baldessari, A; Roffler, S ; Kiem, HP; Fuller, DH; Lieber, A | Human gene therapy 33(7-8), 389-403 | | | |
| 2022 | Inhibition of gut microbial β-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis | Cheng, KW; Tseng, CH; Chen, IJ; Huang, BC; Liu, HJ; Ho, KW; Lin, WW; Chuang, CH; Huang, MY; Leu, YL; Roffler, SR ; Wang, JY; Chen, YL; Cheng, TL | Pharmacological research 177, 106115 | | | |
| 2020 | PEGylated Liposomal Methyl Prednisolone Succinate does not Induce Infusion Reactions in Patients: A Correlation Between in Vitro Immunological and in Vivo Clinical Studies. | Bavli, Y; Chen, BM; Roffler, SR ; Dobrovolskaia, MA; Elnekave, E; Ash, S; Barenholz, Y; Turjeman, K | Molecules (Basel, Switzerland) 25(3), 558 | | | |
